<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bicknell B</submitter><funding>private donor</funding><pagination>368</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12786582</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>&lt;b>Background&lt;/b>: Parkinson's disease (PD) involves progressive neurodegeneration with clinical or subclinical disturbance of the gut-brain axis, including altered gastrointestinal motility and enteric nervous system involvement. Clinical studies have reported gut microbiome alterations in PD, with shifts in taxa associated with inflammatory signalling and short-chain fatty acid (SCFA) metabolism. Photobiomodulation (PBM), a non-invasive light therapy, has been investigated as a potential adjunctive treatment for PD, with proposed effects on neural, metabolic, and immune pathways. We previously reported the five-year clinical outcomes in a PBM-treated Parkinson's disease case series. Here we report the five-year gut microbiome outcomes based on longitudinal samples collected from the same</pubmed_abstract><journal>Journal of clinical medicine</journal><pubmed_title>Five-Year Follow-Up of Photobiomodulation in Parkinson's Disease: A Case Series Exploring Clinical Stability and Microbiome Modulation.</pubmed_title><pmcid>PMC12786582</pmcid><funding_grant_id>NA</funding_grant_id><pubmed_authors>McLachlan C</pubmed_authors><pubmed_authors>Kiat H</pubmed_authors><pubmed_authors>Bicknell B</pubmed_authors><pubmed_authors>Liebert A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Five-Year Follow-Up of Photobiomodulation in Parkinson's Disease: A Case Series Exploring Clinical Stability and Microbiome Modulation.</name><description>&lt;b>Background&lt;/b>: Parkinson's disease (PD) involves progressive neurodegeneration with clinical or subclinical disturbance of the gut-brain axis, including altered gastrointestinal motility and enteric nervous system involvement. Clinical studies have reported gut microbiome alterations in PD, with shifts in taxa associated with inflammatory signalling and short-chain fatty acid (SCFA) metabolism. Photobiomodulation (PBM), a non-invasive light therapy, has been investigated as a potential adjunctive treatment for PD, with proposed effects on neural, metabolic, and immune pathways. We previously reported the five-year clinical outcomes in a PBM-treated Parkinson's disease case series. Here we report the five-year gut microbiome outcomes based on longitudinal samples collected from the same</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-09T03:09:34.501Z</modification><creation>2026-06-09T03:07:22.233Z</creation></dates><accession>S-EPMC12786582</accession><cross_references><pubmed>41517622</pubmed><doi>10.3390/jcm15010368</doi></cross_references></HashMap>